# US 2010/0166775 A1 · S100a9 interaction screening method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166775 A1
- Document ID: US20100166775A1
- Status: Published application
- Kind: A1
- Application number: 12/597,735
- Filed: 2008-04-24
- Published: 2010-07-01
- Earliest claimed: 2007-04-26
- Assignees: Active Biotech AB
- Inventors: Per Bjork; Fredrik Ivars; Tomas Leanderson
- Web page: https://patentgrep.com/patent/US20100166775A1

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/18: against material from animals or humans
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising: -determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or -determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.

## Claims

### Claim 1

A method of identifying a compound for use in therapy which modulates the interaction of S100A9 with a ligand comprising:
(i) determining whether a candidate compound is capable of modulating the interaction of S100A9 with RAGE or the interaction of S100A9 with a TLR (Toll like receptor), or
(ii) determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S100A9 with RAGE or the binding of S100A9 with a TLR,
to thereby identify whether the compound may be used in therapy, wherein optionally the method is carried out in the presence of calcium and zinc ions.

### Claim 2 (depends on 1)

A method according to claim 1(ii) wherein said determining is carried out by measuring whether the candidate compound binds the site on S100A9 which is bound by RAGE or the site on S100A9 which is bound by a TLR.

### Claim 3 (depends on 1)

A method according to claim 1 which tests whether the compound is capable of inhibiting the interaction of S100A9 with RAGE or a TLR.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the therapy is cancer therapy or immunotherapy and/or wherein the TLR is TLR4.

### Claim 5 (depends on 1)

A method according to claim 1 wherein:
said ligand and/or S100A9 are present in isolated, and/or one of the said ligand or S100A9 are immobilized to a solid surface, or
(ii) during the method the effect of the candidate substance on the binding of the ligand to S100A9 is measured over at least 60 to 1200 seconds, preferably 120 to 400 seconds, to allow the kinetics of binding to be observed, or
(iii) the dose dependency of the candidate compound on the binding between the ligand and S100A9 is measured, or
(iv) the detection of binding is carried out in the presence of about 10 uM of zinc ions and about 1mM of calcium ions

### Claim 6 (depends on 1)

A method according to claim 1 which comprises
(i) contacting the candidate compound with S100A9 and determining whether the compound is able to inhibit binding of said S100A9 with RAGE, or
(ii) contacting the candidate compound with RAGE and determining whether the compound is able to inhibit binding of said RAGE with S100A9, or
(iii) contacting the candidate compound a S100A9/RAGE complex and determining whether the candidate compound causes dissociation of the complex.

### Claim 7 (depends on 1)

A method according to claim 1 wherein a fragment and/or homologue of S100A9 and/or RAGE and/or a TLR4 is used, which fragment or homologue is optionally in the form of a fusion protein.

### Claim 8 (depends on 1)

A method according to claim 1 wherein:
(i) a fragment and/or homologue of S100A9 is used which is capable of binding RAGE and/or zinc, and/or
(ii) a fragment and/or homologue of RAGE or a TLR is used which is capable of binding S100A9, and/or
(iii) RAGE or TLR are glycosylated, optionally by expressing them in a mammalian cell.

### Claim 9 (depends on 1)

A method according to claim 1 wherein detection of binding is carried out in conditions in which RAGE and/or TLR4 would not bind to other S100 proteins, and optionally in conditions in which RAGE and/or TLR4 would not bind to S100A1, S100A12, S100B or S100P.

### Claim 10 (depends on 1)

A method according to claim 1 which determines whether:
(i) the compound fits a 1:1 model of binding (one site-competition model), or
(ii) the compound has an IC50 of between 1 nM to 200 uM, or
(iii) the compounds causes inhibition as shown in FIG. 7A, 7B or 7C, or
(iv) the compound decreases the on-rate for the binding of S100A9 to the ligand,
and optionally the compound is selected based on (i), (ii), (iii) or (iv).

### Claim 11 (depends on 1)

A method according to claim 1 in which:
(i) S100A9 is present in the form of a monomer, dimer or multimer that consists only of S100A9 and/or in the form of a S100A8/S100A9 complex, and/or
(ii) the ligand is present in the form of a monomer or dimer

### Claim 12 (depends on 1)

A method according to claim 1 wherein:
the identified compound is further tested to determine whether it reduces an immune response, optionally using a cell based assay or an animal model, and/or
(ii) wherein at least 100,000 different compounds are tested by the method of claim 1 and of these at least 10,000 are further tested to determine whether they reduce an immune response.

### Claim 13 (depends on 12)

A method according to claim 12 wherein the cell based assay comprises monocytes which express S100A9, and is preferably a mixed lymphocyte reaction.

### Claim 14 (depends on 1)

A method according to claim 1 further comprising determining whether the identified compound has therapeutic efficacy in an animal model, wherein optionally the animal model is a cancer model, an autoimmune disease model or a model of an inflammatory condition.

### Claim 15 (depends on 1)

A method according to claim 1 further comprising formulating the identified compound into a pharmaceutical composition.

### Claim 16 (depends on 1)

A method according to claim 1 comprising identifying a compound by a method according to claim 1 and administering the identified compound to an individual in need of therapy.

### Claim 17 (depends on 1)

An antibody that specifically binds to an epitope on S100A9 which epitope is
(i) present in a region of S100 A9 which binds to TLR4 or RAGE, and/or
(ii) specifically bound by an antibody that comprises the variable chains shown in SEQ ID NO: 18 and 20,
wherein the antibody is optionally identifiable by the method of claim 1.

### Claim 18 (depends on 17)

Antibody according to claim 17 which is capable of:
(i) inhibiting the binding of S100A9 to either TLR4 or RAGE, and/or
(ii) stimulating TNFα production in monocytes.

### Claim 19 (depends on 17)

An antibody according to claim 17 which is obtainable by immunizing a S100A9 null mouse with S100A9.

### Claim 20 (depends on 17)

A method of treating cancer or a method of immunotherapy comprising administering an antibody as defined in claim 17 to an individual in need of therapy.
